Peritoneal (Abdominal Mesothelioma)
The Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions
Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…
Read MoreA case of diffuse malignant peritoneal mesothelioma: case report and literature review
Irish Journal of Medical Science 2026 May 19 [Link] Qian Zhao, Kangwei Xiong, Qiaoyun Wang, Lijiu Zhang Abstract Introduction: Diffuse malignant peritoneal mesothelioma (DMPM) is a very rare and life-threateningmalignant tumor. Case: We present a report of a rare case of a 70-year-old female patient with emaciation and poor appetite as manifestations. The characteristics of…
Read MoreMolecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas
Translational Oncology 2026 July [Link] Seddig Momenkhan, Marie Morfouace, Vahan Kepenekian, Olivier Glehen, Laurent Villeneuve, Julio Oliveira, Sabine Tejpar, Sylvie Isaac, Juliette Fontaine, Jean-Yves Blay, Julien Péron, Nazim Benzerdjeb Abstract Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited therapeutic options upon progression. Two genomic profiling initiatives were launched to implement personalized medicine in…
Read MoreMolecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas
Translational Oncology 2026 July [Link] Seddig Momenkhan, Marie Morfouace, Vahan Kepenekian, Olivier Glehen, Laurent Villeneuve, Julio Oliveira, Sabine Tejpar, Sylvie Isaac, Juliette Fontaine, Jean-Yves Blay, Julien Péron, Nazim Benzerdjeb Abstract Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited therapeutic options upon progression. Two genomic profiling initiatives were launched to implement personalized medicine in…
Read MorePIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions
Digestive Surgery 2026 May 12 [Link] Arianna Castagna, Aphrodite Fotiadou, Ali Ramouz, Preslava Gesheva, Niall Brindl, Wiebke Solass, Andreas Brandl Abstract Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy…
Read MoreDevelopment of Mesothelioma in Organ Transplant Recipients: A Comprehensive Study of 10 Cases
Archives of Pathology & Laboratory Medicine 2026 May 11 [Link] Huihua Li, Andre E Nel, Sergio Pina-Oviedo, John M Carney, Carolyn H Glass, Thomas A Sporn, Richard Attanoos, Aliya N Husain, Sonja Klebe, Beiyu Liu, Victor L Roggli, Elizabeth N Pavlisko Abstract Context.—: The development of malignancy after organ transplant has been well recognized as…
Read MorePrognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma
Clinical Lung Cancer 2026 June [Link] Keval Yerigeri, Manjistha Sengupta, Jingli Zhang, Jeevan Puthiamadathil, Raffit Hassan Abstract Background: Mesothelioma is an aggressive malignancy with poor outcomes, particularly when diagnosed at advanced stages. This study evaluated the prognostic value of tumor-specific biomarkers: soluble mesothelin-related peptide (SMRP), megakaryocyte potentiating factor (MPF) and CA125; inflammatory markers: C-reactive protein…
Read MoreThe genetics of cancer heterogeneity and mesothelioma
Frontiers in Oncology 2026 March 16 [Link] Lucian R Chirieac, Ritu Gill, Richard Attanoos Abstract Diffuse mesothelioma is an invasive cancer that originates from the cells in the smooth tissue lining (serosal membrane) that surrounds various body cavities. While most cases originate in the pleural lining of the thoracic cavity, a subset primarily involves the…
Read MoreThe genetics of cancer heterogeneity and mesothelioma
Frontiers in Oncology 2026 March 16 [Link] Lucian R Chirieac, Ritu Gill, Richard Attanoos Abstract Diffuse mesothelioma is an invasive cancer that originates from the cells in the smooth tissue lining (serosal membrane) that surrounds various body cavities. While most cases originate in the pleural lining of the thoracic cavity, a subset primarily involves the…
Read MorePretreatment volume-based 18F-FDG PET/CT parameters as prognostic indicators in malignant peritoneal mesothelioma patients
Japanese Journal of Radiology 2026 March 21 [Link] Kazuhiro Kitajima, Kosuke Matsuda, Hiroyuki Yokoyama, Toshiyuki Minami, Akifumi Nakamura, Kozo Kuribayashi, Takashi Kijima, Koichiro Yamakado Abstract Objective: This study was conducted to examine relationships of pretreatment volume-based quantitative 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters with overall survival (OS) in malignant peritoneal mesothelioma (MPeM) patients.…
Read More
Skip to content